Ardelyx, Inc. (ARDX)
3.82
+0.06
(+1.60%)
USD |
NASDAQ |
Sep 02, 15:49
Ardelyx Cash from Investing (Quarterly) : 22.66M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.66M |
| March 31, 2026 | -9.995M |
| December 31, 2025 | 3.776M |
| September 30, 2025 | -50.51M |
| June 30, 2025 | 34.92M |
| March 31, 2025 | 2.851M |
| December 31, 2024 | -41.62M |
| September 30, 2024 | 2.341M |
| June 30, 2024 | 23.53M |
| March 31, 2024 | -2.572M |
| December 31, 2023 | -29.57M |
| September 30, 2023 | -32.70M |
| June 30, 2023 | -59.21M |
| March 31, 2023 | -9.777M |
| December 31, 2022 | 1.441M |
| September 30, 2022 | -0.832M |
| June 30, 2022 | 15.47M |
| March 31, 2022 | 2.332M |
| December 31, 2021 | 22.10M |
| September 30, 2021 | 18.13M |
| June 30, 2021 | 8.234M |
| March 31, 2021 | 2.485M |
| December 31, 2020 | -3.57M |
| September 30, 2020 | 9.594M |
| June 30, 2020 | 13.42M |
| Date | Value |
|---|---|
| March 31, 2020 | -50.88M |
| December 31, 2019 | -55.46M |
| September 30, 2019 | 23.45M |
| June 30, 2019 | 25.40M |
| March 31, 2019 | 29.98M |
| December 31, 2018 | 22.19M |
| September 30, 2018 | 10.09M |
| June 30, 2018 | -61.04M |
| March 31, 2018 | -1.135M |
| December 31, 2017 | 11.22M |
| September 30, 2017 | 14.81M |
| June 30, 2017 | 16.29M |
| March 31, 2017 | 22.97M |
| December 31, 2016 | -59.23M |
| September 30, 2016 | -71.35M |
| June 30, 2016 | -0.295M |
| March 31, 2016 | -0.20M |
| December 31, 2015 | -0.454M |
| September 30, 2015 | -0.68M |
| June 30, 2015 | -1.265M |
| March 31, 2015 | -1.055M |
| December 31, 2014 | -1.032M |
| September 30, 2014 | -0.088M |
| June 30, 2014 | |
| March 31, 2014 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| REGENXBIO, Inc. | 65.92M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.399M |
| Cash from Financing (Quarterly) | 49.72M |
| Free Cash Flow | -17.92M |
| Free Cash Flow Per Share (Quarterly) | -0.0258 |
| Free Cash Flow to Equity (Quarterly) | -54.34M |
| Free Cash Flow to Firm (Quarterly) | -0.1468M |
| Free Cash Flow Yield | -1.92% |